{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-354690","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2021-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.948280+00:00","generated_at":"2026-06-28T01:46:41.989057+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AlloVir announces positive preliminary Phase 2 data for posoleucel in virus prevention in high-risk allo-HCT patients","bullets":["No end-organ viral disease observed in 23 high-risk allo-HCT patients receiving posoleucel.","Only 3 of 138 possible clinically significant infections occurred; 11 of 13 patients through Week 14 free of infection.","FDA agreed in principle to advance to Phase 3 registrational trial expected to start in 1H 2022.","Posoleucel targeting six viruses: AdV, BKV, CMV, EBV, HHV-6, and JCV."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-354690","json":"https://secwatch.observer/filing/0001193125-21-354690.json","markdown":"https://secwatch.observer/filing/0001193125-21-354690.md","text":"https://secwatch.observer/filing/0001193125-21-354690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312521354690/0001193125-21-354690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312521354690/d261161d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:46:41.989057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}